O. Davies
Gregory University Uturu(NG)Virginia Tech(US)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Psoriasis: Treatment and Pathogenesis, COVID-19 Clinical Research Studies, Systemic Lupus Erythematosus Research
Most-Cited Works
- → Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial(2018)130 cited
- → Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis(2016)112 cited
- → Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA(2017)96 cited
- → Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX(2012)82 cited
- → Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial(2012)73 cited
- → Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction(2020)70 cited
- → Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial(2011)44 cited
- → Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis(2017)37 cited
- → A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis ‘CRP-negative’(2018)33 cited
- → Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials(2023)30 cited